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Abstract
Allelic variants of genes encoding for the Fc gamma receptors IIIA and IIA have
been associated with the clinical response to cell-depleting antibodies in lym-
phoma patients. Here, we tested the hypothesis that FCGR3A and FCGR2A
high-affinity polymorphisms predict clinical outcomes to alemtuzumab therapy
in 85 patients with relapsing-remitting multiple sclerosis. No differences in clin-
ical and MRI-based efficacy parameters, the development of severe infusion-as-
sociated reactions and secondary autoimmune diseases during a 2 year follow-
up was observed based on FCGR3A or FCGR2A polymorphisms. This study
does not support the use of FCGR genetic variants to predict clinical outcomes
to alemtuzumab.
Introduction
Alemtuzumab (Sanofi Genzyme, Cambridge, MA) is a
lymphocyte-depleting humanized monoclonal IgG1 kappa
antibody that selectively targets CD52, an antigen highly
expressed on T and B cells. It is currently approved for
highly active relapsing-remitting multiple sclerosis (RR-
MS) in over 50 countries, and data from initial treatment
cohorts as well as extension studies of phase III clinical
trials provided evidence that alemtuzumab can induce
prolonged disease remission with no evidence for disease
activity in more than 50% of treated patients.1,2 While
the most common adverse events of alemtuzumab therapy
are mild and moderate infusion-associated reactions
(IARs), a major concern with its use is the high risk of
developing secondary autoimmune diseases (SAD) which
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peak around year 3 after treatment initiation with thyroid
autoimmune disease (30–40% of patients) and immune
thrombocytopenia (1–3% of patients) being the most fre-
quent conditions.1,2 Identification of biomarkers that can
predict the clinical efficacy of alemtuzumab or the occur-
rence of adverse events would be of great value for the
management of patients with MS.
Lymphocyte-depleting antibodies such as alemtuzumab
lyse target cells through IgG Fc-mediated effector func-
tions such as antibody-dependent cell-mediated cytotoxic-
ity (ADCC), antibody-dependent cellular phagocytosis
(ADCP), complement-dependent cytotoxicity (CDC), and
by induction of apoptosis. ADCC and ADCP require
engagement and cross-linking of activating FccR
expressed by immune effector cells. In preclinical models,
FccR-mediated cytotoxicity contributes substantially to
the efficacy of depleting antibodies such as the anti-HER2
antibody trastuzumab, rituximab, and alemtuzumab,3,4
and higher affinity allotypic forms of the human activat-
ing FccRIIIA as well as genotypic variants of the activat-
ing FccRIIA were shown to be associated with improved
clinical outcomes in rituximab-treated lymphoma patients
in some 5–7 but not all 8 studies.
The clinical efficacy of alemtuzumab to induce durable
disease remission in MS is believed to involve the initial
elimination of pathogenic lymphocytes.9 While peripheral
blood leukocytes are usually efficiently depleted by alem-
tuzumab, FccR binding affinities of alemtuzumab might
additionally determine its efficacy to eliminate pathogenic
T and B cells that are less accessible and reside at sites of
inflammation such as lymphoid tissues or the central ner-
vous system.10 Expression of the high-affinity V allele with
a valine at amino acid position 158 of FCGR3A results in
tighter binding of the FccRIIIA to IgG1 and IgG3, whereas
the low-affinity F allele with phenylalanine at this position
is associated with decreased binding to IgG, resulting in less
efficient ADCC.11,12 Similarly, the high-affinity H allele
with histidine at amino acid position 131 of FCGR2A
results in greater affinity of FccRIIA for IgG2, whereas the
low-affinity R allele correlates with decreased IgG binding.
Here we investigated whether FccRIIIA and FccRIIA poly-
morphisms are associated with clinical outcomes to alem-
tuzumab treatment in patients with MS.
Subjects and Methods
Patients and biomaterial
All patients were recruited in the Department of Neurology
at the University Hospital M€unster, Germany. 85 patients
with RR-MS on alemtuzumab treatment (Table 1) were
included in the current study. For some patients not all
parameters investigated were available which resulted in
analyses of n = 85 – x for some characteristics. These drop-
outs included: NEDA-3, one patient (F/F group); MRI sta-
bility, two patients (F/F and V/V groups) for FccRIIIA and
NEDA-3, one patient (R/R group); MRI stability, two
patients (H/R and R/R groups) for FccRIIA. PBMCs were
isolated from ethylenediaminetetraacetic acid blood derived
from these patients during blood draws between 2014 –
2017 and cryopreserved as previously described.13
Standard protocol approvals, registrations,
and patient consents
This study was performed according to the Declaration of
Helsinki and approved by the local ethics committee
(2014-398-f-S). All patients gave written informed consent.
DNA isolation
DNA was isolated using Qiagen’s DNeasy Blood & Tissue
Kit (Cat No.: 69506) according to the manufacturer’s rec-
ommendation.
PCR testing and optimization
PCR primers were designed to amplify the region of the
two SNPs of interest in FCGR2A (NP_067674.2 position
166) and FCGR3A (NP_000560.5, position 212). Due to
high homology of FCGR3A, primers were designed in a
region allowing the specific amplification of the FCGR3A
gene. The PCRs were tested on a gradient and the opti-
mal annealing temperature was chosen.
The analytical procedure was tested using six blood sam-
ples derived from donors with known FCGR2A and
FCGR3A genotypes recruited at the University Hospital
Erlangen, Germany. The results of the test runs are shown in
Table 2.
PCR amplification
PCR products were amplified in a 25 µL reaction volume
containing 0.3 µmol/L of each primer, 1.5 µmol/L MgCl2,
200 µmol/L of each dNTP, 0.02 U µl-1 DNA polymerase
Table 1. Demographic characteristics of RR-MS Patients (n = 85).
Female 49 (57.6%)
Age (mean, median, SD) 35.78, 35, 9.66
Age range (years) 18–58
Treatment na€ıve 15 (17.6%)
Prior treatment 70 (82.4%)
Patients with ≥ 2 relapses in the 2 years
prior to 1st infusion
60 (70.6%)
EDSS at baseline (mean, median, SD) 2.8, 2.5, 1.5
Ethnicity: Caucasian 85 (100%)
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(kappa robust; kappa Biosystems, KK5024), and 25 ng
DNA of the sample. PCR cycle conditions are given in
Table 3 and 4.
Sanger sequencing
The PCR products were purified, and bi-directionally
Sanger sequenced at Microsynth (Balgach, Switzerland)
using the two PCR primers for FCGR2A. In case of the
FCGR3A gene an internal forward primer (FCGR3A_-
For02: GGGGTGTCTGTGTCTTTCAG) as well as the
reverse PCR primer were used for the Sanger sequencing.
The sequences were aligned against the reference
sequences derived from GenBank (and any SNPs were
recorded with Soft Genetics Mutation Surveyor v4.0.9
software).
Statistical analysis
The distributions of positive versus negative clinical and
radiological outcomes for patients in different genotypic
groups were compared using the two-sided Fisher’s exact
test via Prism version 7.0a for Mac OSX (Graphpad Soft-
ware, Inc) and corrected p-values (Bonferroni correction)
were calculated with the p.adjust function of the “stats”
package (version 3.6.0) with R (http://www.R-project.org).
A p-value < .05 was considered statistically significant.
Results
Study population characteristics
Data were derived from 85 patients, of whom 49 (58%)
were female. The mean age of patients at initial treatment
with alemtuzumab was 35.8 years (SD 9.7). Patients
received 12 mg of alemtuzumab administered intra-
venously daily for five consecutive days and again one
year later for three consecutive days. The median
expanded disability status scale (EDSS) at baseline was 2.8
(interquartile range [IQR] 2). Mean relapse frequency
prior to treatment was 2.6 relapses in the last two years
before commencement of alemtuzumab (SD 1.8). The
mean number of treatments prior to alemtuzumab was
2.3 (SD 1.7) and included natalizumab (n = 28), fin-
golimod (n = 18), IFNb (n = 9), dimethylfumarat
(n = 6), glatirameracetat (n = 4), teriflunomide (n = 2),
Table 2. PCR design.
Sample
Sequence
read RNA Accession
Protein
Accession
Nucleotide
Position
Reference
Nucleotide
Mutation
Nucleotide
Amino Acid
Position
Reference
Amino
Acid
Mutation
Amino
Acid
FcgRIIA-131 H/H for NM_021642.3 NP_067674.2 c.497 A 166 H
rev NM_021642.3 NP_067674.2 c.497 A 166 H
FcgRIIA-131 H/R for NM_021642.3 NP_067674.2 c.497 A AG 166 H H/R
rev NM_021642.3 NP_067674.2 c.497 A AG 166 H H/R
FcgRIIA-131 R/R for NM_021642.3 NP_067674.2 c.497 A G 166 H R
rev NM_021642.3 NP_067674.2 c.497 A G 166 H R
FcgRIIIA-158 F/F for NM_000569.6 NP_000560.5 c.634 T 212 F
rev NM_000569.6 NP_000560.5 c.634 T 212 F
FcgRIIIA-158 F/V for NM_000569.6 NP_000560.5 c.634 T TG 212 F F/V
rev NM_000569.6 NP_000560.5 c.634 T TG 212 F F/V
FcgRIIIA-158 V/V for NM_000569.6 NP_000560.5 c.634 T G 212 F V
rev NM_000569.6 NP_000560.5 c.634 T G 212 F V
Table 3. PCR primers and annealing temperatures used for the PCR amplification.
PCR Primers Sequence Amplicon Length Annealing Temperature
FCGR2A_Ex04 FCGR2A_Ex04_fw GCATCTTCATTTCTGTCTGCCA 493 63 °C
FCGR2A_Ex04_rev CTCCAGTGCCCAATTTTGCT
FCGR3A_Ex04 FGR3A_For03 GTGTTTACATTGAGTTCTCCTTC 873 63 °C
FCGR3A_Ex04_rev TCCTCCCAACTCAACTTCCC
Table 4. PCR cycle sequencing conditions; 35 cycles.
PCR Step Description Temp (°C) Duration (sec)
1 Initial Denaturation 95 180
2 Denaturation 95 20
3 Annealing 63 20
4 Elongation 72 30
5 Final Elongation 72 45
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mitoxantrone (n = 1), azathioprine (n = 1), and siponi-
mod (n = 1). Fifteen patients did not receive any pre-
treatment (Table 1).
Clinical outcomes
The total number of patients who experienced at least
one relapse during the first two years of the follow-up
period was 34 (40%). Twenty patients (24%) met the def-
inition for confirmed disease progression (CDP). NEDA-
3, as defined by absence of clinical relapse, no confirmed
EDSS disability progression, no new gadolinium enhanc-
ing lesions and no new or enlarging T2 lesions, was
observed in 41 (49%) of patients. Severe IAR included
according to the Common Terminology Criteria for Adverse
Events (CTCAE), death, life-threatening consequences,
fetal damage, and need for urgent hospitalization and
were observed in 30 patients (35%). A total of 24 (28%)
patients developed SAD. Observed SAD entities included
Graves’ disease (n = 16), idiopathic thrombocytopenic
purpura (ITP) (n = 2), vitiligo (n = 2), autoimmune
hepatitis (n = 1), autoimmune thyroid disease (AITD)
(n = 5), and hemophagocytic syndrome (n = 1). Two
patients developed more than one SAD (patient 1:
Graves’ disease, ITP; patient 2: AITD, Vitiligo and
autoimmune hepatitis). The mean time point of SAD
manifestation was at 22 months (SD: 12.9, range: 6–
51 months). Six patients (7%) developed acute acalculous
cholecystitis (AAC).
Prevalence of FCGR3A and FCGR2A
genotypes
Prior to genotyping the patient samples via bi-directional
Sanger sequencing, PCR conditions were optimized and
validated using six blood samples from individuals with
known FCGR3A and FCGR2A genotypes. Among the 85
RR-MS patients investigated, 11 (13%) carried the high-
affinity FCGR3A 158 V/V genotype, 41 (48%) were
heterozygous carriers (FCGR3A 158 V/F), and 33 (39%)
were homozygous for FCGR3A 158 F/F. With respect to
the FCGR2A 131 polymorphism, 21 patients were (25%)
38.8%  n=33 F/F
12.9%  n=11 V/V
48.2%  n=41 F/V
FCGRIIIA
n=85
24.7%  n=21 H/H
32.9%  n=28 R/R
42.4%  n=36 H/R
FCGRIIA
A B
Figure 1. Fcc receptor polymorphism frequency distribution for FccRIIIA (A) and FccRIIA (B) within the study cohort of 85 RR-MS patients
previously treated with alemtuzumab.
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genotyped as FCGR2A 131 H/H, 36 (42%) were
heterozygous FCGR2A 131 R/H carriers, and 28 (33%)
were homozygous for FCGR2A 131 R/R (Fig. 1). Fre-
quency distribution of allelic variants in our study were
similar to those reported for Caucasians in previous
studies.5,6
Association of FCGR genotypes with clinical
outcomes
Twenty-seven percent of patients with the FCGR3A
158 V/V genotype did not experience any relapses during
the 2 year follow-up period as opposed to 67% for
FCGR3A 158 F/F and 63% for FCGR3A F/V carriers.
Absence of CDP was documented for 63% of patients
with V/V, 87 % of patients with F/F and 71% of patients
with F/V genotypes. Sixty percent (V/V), 69% (F/F) and
66% (F/V) respectively showed MRI stability as defined
by no new or enlarging T2 or gadolinium-enhancing
lesion. NEDA-3 criteria were met by 18% of the V/V
group versus 59% (F/F) and 49% (F/V). Severe infusion-
associated reactions were experienced by 36% of patients
with V/V, 21% with F/F and 46% with F/V genotypes. In
55% of V/V secondary autoimmune diseases occurred as
opposed to 30% of F/F and 20% of F/V (Fig. 2A).
Forty seven percent of the FCGR2A 131 H/H carriers
were relapse-free during the first 2 years after alem-
tuzumab treatment initiation compared to 57% of R/R
and 69% of H/R carriers. Absence of CDP was noted in
71% (H/H), 68% (R/R) and 86% (H/R) of carriers,
respectively. 52% (H/H), 56% (R/R) 83% (H/R) depicted
stable MRI activity and NEDA-3 status was achieved in
38% (H/H), 41% (H/R) and 61% (R/R) of study partici-
pants. Severe IAR occurrence was distributed as follows:
33% (H/H), 29% (R/R) and 42% (H/R). 24% (H/H),
36% (R/R), and 25% (H/R) developed SADs (Fig. 2B).
Moreover, no statistically significant differences in clinical
efficacy outcomes, the development of severe IARs and
SADs were observed in patients homozygous for both
high-affinity variants (FCGR3A 158 V/V; FCGR2A 131 H/
H, designated V/V3A-H/H2A) as compared to patients
homozygous for both low-affinity FccRs (FCGR3A 158 F/
F; FCGR2A 131 R/R, designated F/F3A-R/R2A) (Fig. 3).
Altogether, FCGR3A and FCGR2A genotypes were not
significantly associated with any of the aforementioned
clinical or radiological outcomes following alemtuzumab
therapy.
Discussion
Our report is the first investigation into the impact of
FccR polymorphisms on clinical outcomes to lympho-
cyte-depleting antibody therapy in patients with MS. No
differences in clinical efficacy parameters, the develop-
ment of severe IARs and SADs in response to alem-
tuzumab therapy were observed in patients with RR-MS
based on FCGR3A or FCGR2A polymorphisms. These
data indicate that FCGR3A and FCGR2A polymorphisms
are not associated with clinical outcomes to alemtuzumab
in MS.
Our study was motivated by epidemiological investiga-
tions that reported an association between the low affinity
FCGR3A 158 F/F genotype in patients with non-Hodgkin
B-cell lymphoma and a poor clinical response to ritux-
imab, presumably due to incomplete ADCC-mediated
depletion of tumor cells.5–7,14 In vitro studies demon-
strated that alemtuzumab depletes human lymphocytes
through both Fc-mediated ADCC and CDC.4 In vivo, cell
depletion by alemtuzumab is reported to be predomi-
nantly mediated by ADCC and largely independent of
complement as reported in transgenic mice expressing
human CD52 15 and in an experimental murine model of
T cell leukemia.16 While the mechanisms by which alem-
tuzumab depletes lymphocytes in humans and exerts its
beneficial effects in MS are incompletely understood and
might require complement-dependent pathways, our data
should not be interpreted to minimize the impact of
ADCC as an important mechanism of action. Rather,
FccR polymorphisms may not strongly influence the clin-
ical efficacy of alemtuzumab therapy. Our findings are
based on a relatively small number of subjects (n = 85)
and clearly require validation in larger cohorts. Moreover,
we cannot exclude potentially confounding effects of neu-
tralizing antibodies to alemtuzumab which may occur in
individual patients within the first 2 years after treatment
initiation.17
Figure 2. Clinical and radiological characteristics of RR-MS patients after alemtuzumab therapy stratified by FccR polymorphisms. (A) Data for
homozygous 158V/V (high-affinity), homozygous 158F/F and heterozygous 158F/V FccRIIIA polymorphisms and (B) homozygous 131H/H (high-
affinity), homozygous 131R/R and heterozygous 131H/R FccRIIA polymorphisms are depicted. For some characteristics not all patient data were
available. For the following analyses the n was: 84, NEDA-3/ FccRIIIA (1 patient missing, F/F group); 83, MRI stability/ FccRIIIA (2 patients missing,
F/F and V/V groups); 84, NEDA-3/ FccRIIA (1 patient missing, R/R group) and 83, MRI stability/ FccRIIA (2 patients missing, H/R and R/R groups).
The remaining analyses were carried out on all 85 patients. Shown are percentages of the respective genotypic groups as bargraphs and absolute
numbers of patients in white. Statistical analysis: Two-sided Fischer’s exact test with Bonferroni correction for multiple testing was applied on
absolute patient numbers. A p-value < .05 was considered statistically significant. Abbreviations: CDP, confirmed disability progression; MRI,
magnetic resonance imaging; NEDA, no evidence of disease activity; IAR, infusion-associated reactions; SAD, secondary autoimmune disease
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Given the clinical efficacy and increasing use of lym-
phocyte-depleting antibodies in the therapeutic landscape
of MS and other neurological diseases, our initial assess-
ment provides incentive to conduct larger prospective
studies in order to evaluate the impact of FccR polymor-
phisms on clinical outcomes and in vivo mechanisms of
therapeutic antibodies in MS.
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percentages of the respective genotypic groups as bargraphs and absolute numbers of patients in white. Statistical analysis: Two-sided Fischer’s
exact test was applied on absolute patient numbers. A p-value < .05 was considered statistically significant. Abbreviations: CDP, confirmed
disability progression; MRI, magnetic resonance imaging; NEDA, no evidence of disease activity; IAR, infusion-associated reactions; SAD, secondary
autoimmune disease.
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